News and Announcements
Walker Capital develop FREE Net return investment calculator
- Published October 14, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Walker Capital has developed a free Net Return Investment Calculator.
- This calculator allows clients and companies to simulate their investment in Walker Capital’s products based on real trading data.
- The calculator can also calculate the compounded net return.
Walker Capital has developed a free Net Return Investment Calculator which allows clients ad companies to simulate their investment in Walker Capital’s products based on real trading data.
The calculator can simulate clients investment in Walker Capital’s products based on real trading data over a selected investment period.
The Net Return Investment Calculator was set up with the objective of receiving a net return in excess of 20% per annum.
This calculator is Net of Management Fees, Performance Fees and Brokerage/Commission.
The returns are based on actual trading data from real money accounts that trade the same strategies offered by Walker Capital under the Walker Capital Model Portfolios MDA Service.
Access Walker Capital’s FREE Net Return Investment Calculator here.
About Walker Capital
Walker Capital is to raise up to $900,000 for 20% in equity. The capital will be used to fund the expansion of the Company as it increases its marketing campaign aimed at expanding its client base and developing an investment platform for its clients.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
